Bayer Launches Stivarga In Malaysia And Singapore For Terminal Colorectal Cancer Patients To Prolong Survival
This article was originally published in PharmAsia News
Executive Summary
Bayer built upon approvals in the U.S., Europe and Japan to launch Stivarga for the first time in Southeast Asia. Well-established cancer treatment centers in Singapore and Malaysia attract patients in the region as well as far afield from the Middle East.